Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Abbreviated New Drug Application (ANDA)
On October 3, 2025, the FDA unveiled a pilot program that fast‑tracks the review of abbreviated new drug applications (ANDAs) submitted by generic manufacturers that test and produce their products in the United States. The initiative is designed to spur domestic investment, shorten approval timelines, and reinforce the U.S. pharmaceutical supply chain. By rewarding U.S.‑based manufacturing and testing, the FDA hopes to increase the availability of lower‑cost generic drugs. The program builds on the Hatch‑Waxman framework that already governs bioequivalence standards.
Global Generic Drug Affairs
The FDA’s Office of Generic Drugs (OGD) highlighted its expanding global footprint, celebrating the Generic Drug Cluster’s three‑year anniversary and launching a new Request for Information Sharing (RIS) program with Health Canada. The RIS initiative aims to streamline regulatory data...
MedCity Pivot Podcast: A Conversation About Interoperability with Particle Health’s CEO
Particle Health CEO Jason Prestinario discussed the current state of U.S. healthcare interoperability on MedCity’s Pivot podcast. He gave the data‑transmission infrastructure a B‑plus grade but overall usage a C, citing progress from CMS frameworks and multiple exchange networks. Prestinario...
ASCO Abstracts Posted Tomorrow, Full Data Saved for Meeting
The #ASCO26 abstracts will be posted tomorrow at 5 pm EDT. What this means, and what is doesn't. -- No late-breaker abstracts tomorrow. You will not see the plenary session data from $RVMD, Akeso / $SMMT, $JNJ or $LLY....
STAT+: Biotech Execs, Academic Expert Lament Impact of FDA Turnover on Rare Disease Drug Development
Biotech leaders and an academic expert warned that recent turnover among senior FDA officials is creating heightened uncertainty for rare‑disease drug developers. At the STAT Breakthrough Summit West, Mahzi Therapeutics CEO Yael Weiss described constant investor inquiries and a “roller‑coaster”...
New Obstetric Codes Will Replace Bundled Payment — Here’s What to Know
The American Medical Association is replacing the 1990s‑era bundled global obstetric CPT codes with a new set of 12 added, six revised, and 17 deleted codes effective Jan. 1, 2026. The overhaul aligns with ACOG’s push for personalized prenatal schedules, requiring...
Ebola Crisis Sparks Debate Over Global Health Double Standards
The Ebola outbreak in the Democratic Republic of Congo and neighboring Kenya has sparked a heated debate over the speed and leadership of the global response. The World Health Organization faced criticism from U.S. Secretary of State Marco Rubio and...
Kennedy Fires Heads of Task Force that Sets Insurance Coverage Rules
Health Secretary Robert F. Kennedy Jr. fired co‑chairs John Wong and Esa Davis of the U.S. Preventive Services Task Force, ending their terms slated through 2027‑2028. The dismissals were framed as an administrative decision and the letters invite the former...
Value, Focus, and the Future of MedTech: M&A and Divestitures Are Rewriting the Strategic Playbook.
MedTech firms are reshaping portfolios by prioritizing market access, turning it into the primary driver of mergers, acquisitions and divestitures. Leaders now evaluate assets on reimbursement certainty, evidence strength and ASP durability rather than pure innovation. High‑profile deals such as...
FDA Clears INTERACT Meeting for Glafabra’s Fabry Gene Therapy, Paving Way for Single‑Shot Treatment
The U.S. Food and Drug Administration accepted Glafabra Therapeutics’ request for a face‑to‑face INTERACT meeting on July 16, 2026, to discuss its lead Fabry disease gene therapy GT-GLA‑S03. The meeting, granted to only about 30% of applicants, moves the company...
FDA Clears Johns Hopkins AI Tool that Cuts Sepsis Deaths by 20%
The U.S. Food and Drug Administration gave clearance to an AI‑driven early‑warning system from Johns Hopkins University that identifies sepsis up to 48 hours before clinicians suspect it. Early data show a near‑20% reduction in sepsis‑related deaths across dozens of...
Eli Lilly Accuses Church Bishops, Businessmen of Fraud in Trulicity Drug Rebate Scheme
Eli Lilly has filed a civil lawsuit in Miami accusing a Florida mail‑order pharmacy, DrugPlace, and a Tennessee‑based organization linked to the Church of God in Christ of running a six‑year scheme that siphoned more than $200 million in rebates on its...
Dental Intelligence Launches AI‑powered SaaS Tools for Dental Practices
Dental Intelligence, the cloud‑based performance platform for dental offices, announced three AI‑powered capabilities that will be released beginning in Q2 2026. The features are designed to automate workflow, improve case acceptance and keep the human touch in dentistry, underscoring the...
Beyond Compliance: What KLAS’ Brief Reveals About the Real ROI of Legacy Data Decommissioning
KLAS’s May 2026 Data Archiving brief surveyed 36 deep‑adopter health systems to gauge how archives are used beyond compliance. The study found that 60% of participants have no interest in leveraging archived records for AI or research, and only two organizations...
From Fewer Fractions to Smarter Combinations: The State of Radiotherapy in Soft Tissue Sarcoma
A 2026 review in Current Oncology Reports finds that hypofractionated radiotherapy, particle‑beam modalities and immunotherapy combinations are reshaping soft‑tissue sarcoma (STS) treatment. Evidence shows 15‑20‑fraction regimens achieve 85‑90% local‑control rates comparable to conventional 35‑fraction schedules, while cutting treatment time by...
Medtronic Data Back Renal Denervation in the Long Term
Medtronic reported that two EuroPCR abstracts based on the global SYMPLICITY registry show its Symplicity Spyral renal denervation system delivers sustained blood‑pressure reductions over three years. One analysis of 787 patients with prior cardiovascular events recorded a 17.4 mmHg drop in office...
Inside the 'Glass Box': Why One Physician Thinks AI in Medicine Must Show Its Work
Dr. Niki Panich, chief medical officer of Penguin AI and practicing family physician, is championing “glass box traceability” – AI tools that expose the reasoning behind clinical recommendations. She argues that physicians must see at a glance the data, weights,...
House Health Subcommittee Examines Physician Payment Reform
The House Energy and Commerce Committee’s Health Subcommittee is holding a hearing to scrutinize the Medicare Physician Fee Schedule (PFS) and the reforms introduced by MACRA. Lawmakers and medical leaders will discuss persistent payment instability, especially for surgical and specialty...
Cedars-Sinai Deploys OpenEvidence Enterprise Platform to Drive Precision Clinical Decision Support
Cedars‑Sinai has rolled out the OpenEvidence enterprise platform across its entire network, embedding an AI‑driven clinical reference tool directly into the electronic health record. The system surfaces patient‑specific, peer‑reviewed medical literature at the point of care, while also allowing the...
FDA’s Megha Kaushal ASGCT Talk: PFDD, Patient Voices, Decision-Making
At the 2026 ASGCT meeting, FDA Acting Deputy Director Megha Kaushal highlighted the agency’s Patient‑Focused Drug Development (PFDD) initiative, urging early integration of patient and caregiver input into cell and gene therapy trials. She emphasized that families’ lived‑experience data should inform...
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint
Guardant Health announced FDA approval of Guardant360® Liquid CDx, the largest liquid‑biopsy panel on the market, featuring a 100‑fold expanded genomic footprint. The test merges genomic and epigenomic profiling from a single blood draw, delivering several‑fold higher circulating tumor DNA...
IntraBio Receives Regulatory Authorization to Begin Pivotal Phase III Trial of Levacetylleucine in CACNA1A-Related Disorders Across Participating Regions
IntraBio announced regulatory authorization to launch its pivotal Phase III trial of levacetylleucine (AQNEURSA) in CACNA1A‑related disorders across the United States, United Kingdom, European Union and Switzerland. The 12‑week, randomized, double‑blind, placebo‑controlled crossover study will be conducted at twelve multinational sites...
Leading NCI-Designated Cancer Centers Across the Country Leverage ConcertAI’s CancerLinQ to Support Personalized, Evidence-Based Quality Care
ConcertAI announced that the University of Rochester Medicine Wilmot Cancer Institute and UCHealth/University of Colorado Anschutz Cancer Center have joined its CancerLinQ network. The addition expands the platform’s real‑world evidence reach to over 900 sites across all 50 states. CancerLinQ’s...
The Foundation for the National Institutes of Health Announces Recipients of the Deeda Blair Research Initiative for Disorders of the...
The Foundation for the National Institutes of Health announced three new awardees of the Deeda Blair Research Initiative for Disorders of the Brain. Each will receive $200,000 to fund innovative projects aimed at transforming diagnosis and treatment of severe mental...
Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
Incyte and Genesis Molecular AI have broadened their partnership, granting Genesis access to Incyte's proprietary experimental data to train the next‑generation GEMS AI platform. The deal includes a $120 million upfront payment—$80 million in cash and $40 million in equity—plus recurring research funding....
Senate Democrats Move to Roll Back Medicare AI Prior Authorization Pilot
Senate Democrats introduced a resolution under the Congressional Review Act to terminate the Wasteful and Inappropriate Service Reduction (WISeR) model, an AI‑driven prior‑authorization pilot in Medicare. The pilot, active in six states, forces prior approval for services such as skin...
Hospital Device Security Cannot End at Visibility
Modern hospitals now run hundreds of thousands of connected medical, IoT and OT devices, making device visibility a top priority. A recent Asimily survey found 43 % of North American CISOs cite complete visibility as their biggest challenge, yet visibility alone...
WVE-006 RNA Editing Therapy Achieves MZ-Like Phenotype in Alpha-1 Antitrypsin Deficiency Phase 1b/2a Trial
Wave Life Sciences reported that its investigational RNA‑editing drug WVE‑006 generated major‑variant alpha‑1 antitrypsin (M‑AAT) levels comparable to the protective heterozygous Pi*MZ phenotype in patients with homozygous Pi*ZZ AAT deficiency. The Phase 1b/2a RestorAATion‑2 trial showed 64%–59% of circulating AAT was...
The Boston Children’s Experience: Hidden ICU Risk and AI-Driven De-Escalation
Boston Children’s Hospital has spent over a decade deploying AI‑driven clinical intelligence in its pediatric ICUs, shifting the focus from early‑warning alerts to data‑backed de‑escalation. Continuous, high‑frequency physiologic monitoring now provides real‑time risk trajectories that inform decisions on extubation and...
Where Your Out-of-the-Box eQMS Is Probably Underbuilt
Clinical‑stage companies are discovering that eQMS platforms purchased two years ago often fall short of 21 CFR Part 11 requirements. Vendors typically oversell out‑of‑the‑box functionality, leaving audit trails incomplete and access controls too permissive. The gaps become evident only after a...
EQS-News: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
GeoVax Labs warned that the escalating Bundibugyo Ebola outbreak in Central Africa highlights the lack of licensed vaccines for less‑common Ebola strains. The company pointed to its Modified Vaccinia Ankara (MVA) platform, which has shown single‑dose protection against Zaire and...
Derbyshire NHS Selects Psyomics’ Beseen Platform to Support Community Mental Health Transformation
Derbyshire Healthcare NHS Foundation Trust has partnered with digital‑mental‑health specialist Psyomics to deploy its beseen Adult platform across Community Mental Health Teams. The solution automates patient‑reported outcome collection, integrates directly with the Trust’s electronic health records, and aims to ease...
Medicine by Captivity: The Rise of the Hostage Physician
Dr. Joseph Varon’s firsthand account illustrates how U.S. hospitals have become industrial‑scale systems where insurance deadlines and occupancy metrics dictate patient care. He describes ICU overcrowding, staff exhaustion, and administrators pressuring physicians to consider the "insurance clock" rather than clinical...
When the Referee Owns the Team — and Tennessee Changes the Rules
Senate Bill 2040, soon to be signed by Governor Bill Lee, requires pharmacy benefit managers (PBMs) in Tennessee to separate from any pharmacies they own, ending vertical integration that can create conflicts of interest. The legislation targets practices such as...
DHSC Publishes Equality Impact Assessment for the Single Patient Record
Britain’s Department of Health and Social Care released an equality impact assessment for the proposed Single Patient Record (SPR) legislation in the Health Bill. The assessment, based on 2,200 public responses, shows more than three‑quarters of respondents back the SPR,...
The Compliance Bottleneck in Connected Health: Why Cloud-Based Medical Devices Need a Different V&V Approach
Traditional verification and validation (V&V) frameworks assume a static medical device, but cloud‑based platforms continuously evolve, creating a compliance bottleneck. The FDA’s emerging guidance—such as the Pre‑Determined Change Control Plan—offers a pathway for iterative updates but adds significant upfront documentation....
GLP‑1 Weight‑Loss Drugs Show Cardiovascular and Metabolic Gains
GLP‑1 weight‑loss injections, taken by one‑eighth of U.S. adults, are now linked to reduced inflammation, fewer heart‑failure hospitalizations and lower risk of dementia and cancer. Researchers say the findings broaden the drugs’ value beyond weight loss.
FDA Approves Baxdrostat, First‑in‑Class Aldosterone Synthase Inhibitor for Hypertension
The U.S. Food and Drug Administration has approved baxdrostat, AstraZeneca's first‑in‑class oral aldosterone synthase inhibitor, as an add‑on treatment for adults whose hypertension remains uncontrolled despite existing therapy. The decision follows a Phase III trial that demonstrated statistically significant systolic blood‑pressure...
HHS Reorganizes Office for Civil Rights with Religious Bent
The Department of Health and Human Services is reorganizing its Office for Civil Rights, reinstating the Conscience and Religious Freedom Division that was eliminated in 2023. The OCR will now operate three distinct units: civil‑rights enforcement, health‑information privacy and cybersecurity,...
Surescripts Expands Prior Authorization Automation: Slashing Prescription Approval Times as New CMS Interoperability Rules Loom
Surescripts has broadened its Prior Authorization Automation platform, adding 68,000 prescribers across 42 health systems—a 50% increase since December 2025. The automated workflow now delivers a median approval time of just 18 seconds, eliminating manual forms, faxes, and calls. Real‑time...
FDA Review Highlights Single‑Arm Trial Approval Risks
$IBRX -- The FDA accepted the sBLA to expand Anktiva to include the treatment of MNBIC papillary. The PDUFA date is Jan. 6, 2027. Standard review. A positive development for ImmunityBio, but like all things, details matter. Approval...
Parabilis Raises $800M, Eyes IPO to Tackle Undruggable Targets
After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets https://t.co/hKprr9rkJ4 @ByJonGardner $PBLS #biotech #IPO
Hospitals Deploy AI Chatbots and Apps as Home Care Expands, Facing New Regulatory Scrutiny
U.S. health systems are rapidly rolling out AI‑driven chatbots and mobile apps to support home‑based care, freeing more than 17,500 hospital beds and cutting costs by $17 million. At the same time, federal officials are tightening funding rules and Medicare enrollment...
Lithium Cholesterol Sulfate Shows Promise for Alzheimer’s and Autism
Lithium Cholesterol Sulfate: A Novel and Potential Drug for Treating Alzheimer's Disease and Autism Spectrum Disorder https://t.co/RtPZtiGG8k
BARDA Ships Experimental Ebola Antibody to Protect High‑risk Americans
BARDA is coordinating shipment of an experimental antibody treatment for potential use in high-risk Americans exposed to #ebola, HHS tells CNN While they didn't name the treatment, Mapp's MBP134 has shown activity in animal studies against Bundibugyo strain
Ipsen’s Dysport Outlasts Botox in First Head‑to‑Head Spasticity Trial
Ipsen announced that its botulinum toxin product Dysport delivered significantly longer symptom control than rival Botox in the Phase IV DIRECTION trial, a randomized head‑to‑head study of 464 adults with upper‑limb spasticity across 72 sites in the U.S., France and Canada.
Big Pharma Is Gambling on Specialized R&D. Will It Pay Off?
Big pharmaceutical firms are pivoting from broad, diversified pipelines to highly specialized research areas to offset looming revenue gaps from patent expirations and the Inflation Reduction Act’s shortened drug earnings life. Companies such as AstraZeneca are concentrating on nucleic‑acid therapeutics,...
How AI & CMS Are Solving the $4 Trillion Healthcare Crisis
The CMS ACCESS model, effective later in 2025, replaces fee‑for‑service Medicare payments with outcome‑aligned reimbursements, rewarding improvements in A1c and blood pressure rather than provider time. This shift opens a market of roughly 35 million Medicare beneficiaries to AI‑driven digital health...
Why Patient Engagement Is Clinical Trials’ Next Strategic Frontier
The article argues patient engagement is the next strategic priority for clinical trials, especially as decentralized and hybrid models reduce face‑to‑face contact. Simple reminder emails are insufficient; effective engagement requires tailored gamification, real‑time financial incentives, and transparent feedback showing participants...
Scientists Discover Why Alzheimer’s Risk Hits Women so Much Harder
Scientists at UC San Diego analyzed data from over 17,000 adults and found that several modifiable dementia risk factors have a disproportionately larger impact on women’s cognition than men’s. Women reported higher rates of depression, inactivity and sleep problems, while...